Advanced search
Publication Cover
Leukemia & Lymphoma Latest Articles
Submit an article Journal homepage
30
Views
0
CrossRef citations to date
0
Altmetric
Letter to the Editor

Importance of long-term follow-up of autologous stem cell transplantation for mantle cell lymphoma

Colin Stewarta Tom Baker Cancer Centre and University of Calgary, Calgary, CanadaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0009-0007-6614-4970View further author information
ORCID Icon,
Carolyn Owena Tom Baker Cancer Centre and University of Calgary, Calgary, CanadaView further author information
,
Neil Chuab Department of Oncology, Cross Cancer Institute and University of Alberta, Edmonton, CanadaView further author information
,
Anthea Petersb Department of Oncology, Cross Cancer Institute and University of Alberta, Edmonton, CanadaView further author information
,
Mona Shafeya Tom Baker Cancer Centre and University of Calgary, Calgary, CanadaView further author information
,
Alex Balogha Tom Baker Cancer Centre and University of Calgary, Calgary, CanadaView further author information
,
Jeffrey Caoa Tom Baker Cancer Centre and University of Calgary, Calgary, CanadaView further author information
,
Douglas Stewarta Tom Baker Cancer Centre and University of Calgary, Calgary, CanadaView further author information
&
Robert Puckrina Tom Baker Cancer Centre and University of Calgary, Calgary, CanadaView further author information
 show all
Received 31 May 2024, Accepted 22 Jun 2024, Published online: 05 Jul 2024

References

  • Dreyling M, Doorduijn J, Giné E, et al. Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network. Lancet. 2024;403(10441):2293–2306. doi:10.1016/S0140-6736(24)00184-3
  • Hermine O, Hoster E, Walewski J, et al. Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network. Lancet. 2016;388(10044):565–575. doi:10.1016/S0140-6736(16)00739-X
  • Merryman RW, Edwin N, Redd R, et al. Rituximab/bendamustine and rituximab/cytarabine induction therapy for transplant-eligible mantle cell lymphoma. Blood Adv. 2020;4(5):858–867. doi:10.1182/bloodadvances.2019001355
  • Zoellner A-K, Unterhalt M, Stilgenbauer S, et al. Long-term survival of patients with mantle cell lymphoma after autologous haematopoietic stem-cell transplantation in first remission: a post-hoc analysis of an open-label, multicentre, randomised, phase 3 trial. Lancet Haematol. 2021;8(9):e648–e57. doi:10.1016/S2352-3026(21)00195-2
  • Hermine O, Jiang L, Walewski J, et al. High-dose cytarabine and autologous stem-cell transplantation in mantle cell lymphoma: long-term follow-up of the randomized mantle cell lymphoma younger trial of the European Mantle cell lymphoma network. J Clin Oncol. 2023;41(3):479–484. doi:10.1200/JCO.22.01780
  • Sarkozy C, Thieblemont C, Oberic L, et al. Long-term follow-up of rituximab maintenance in young patients with mantle-cell lymphoma included in the LYMA Trial: A LYSA study. J Clin Oncol. 2024;42(7):769–773. doi:10.1200/JCO.23.01586
  • Metzner B, Müller TH, Casper J, et al. Long-term outcome in patients with mantle cell lymphoma following high-dose therapy and autologous stem cell transplantation. Eur J Haematol. 2023;111(2):220–228. doi:10.1111/ejh.13985
  • Martin P, Maddocks K. Does TRIANGLE take down transplantation in mantle cell lymphoma? Lancet. 2024;403(10441):2264–2265. doi:10.1016/S0140-6736(24)00301-5
  • Wang ML, Jurczak W, Jerkeman M, et al. Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma. N Engl J Med. 2022;386(26):2482–2494. doi:10.1056/NEJMoa2201817
  • Hawkes EA, Lee ST, Churilov L, et al. Window study of acalabrutinib & rituximab, followed by chemotherapy & autograft (ASCT) in fit patients with treatment naïve mantle cell lymphoma (MCL): first report of the investigator-initiated Australasian leukaemia & Lymphoma Group NHL33 ‘Wamm’Trial. Blood. 2023;142(Supplement 1):735–735. A doi:10.1182/blood-2023-178403
  • Song Y, Zhou K, Zou D, et al. Zanubrutinib in relapsed/refractory mantle cell lymphoma: long-term efficacy and safety results from a phase 2 study. Blood. 2022;139(21):3148–3158. doi:10.1182/blood.2021014162

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.